LSDrejø skrev:
Citat:
Håbet er derfor at udvikle et kemikalie, der kan godkendes til mennesker. Lignende stoffer, der hæmmer NMDA-receptorerne, er allerede godkendt af de amerikanske lægemiddelmyndigheder, FDA, til behandling af hoste og Alzheimers sygdom.
Resultaterne er offentliggjort i seneste udgave af det videnskabelige tidsskrift Journal of Neuroscience.
Wow, det er ret interessant! Jeg skal prøve at finde artiklen en af de nærmeste dage for at se hvilket stof de har anvendt i studiet - der er mange af NMDA-antagonisterne som er heftige psykoaktiver, blandt andet ketamin, ibogain og PCP.
Edit: Det må være den her:
Journal of Neuroscience skrev:
Amy L. Milton, Jonathan L. C. Lee, Victoria J. Butler, Richard Gardner, and Barry J. Everitt
Behavioural and Clinical Neuroscience Institute, Department of Experimental Psychology, University of Cambridge, Downing Site, Cambridge CB2 3EB, United Kingdom
Correspondence should be addresssed to Amy L. Milton, Department of Experimental Psychology, University of Cambridge, Downing Site, Cambridge CB2 3EB, UK. Email:
alm46@cam.ac.ukThe amygdala has long been considered a primary locus in mediating the effects of previously drug-associated stimuli on subsequent drug-seeking behavior, and the NMDA subtype of glutamate receptor within the amygdala is important for the consolidation of associations between environmental conditioned stimuli and the effects of addictive drugs. Here we demonstrate that amygdala NMDA receptors are also necessary for the reconsolidation of drug-associated memories. Using a behavioral task that specifically measures the conditioned reinforcing properties of a previously drug-paired stimulus, we show that infusion of the NMDA receptor antagonist D(-)-2-amino-5-phosphonopentanoic acid (D-APV) into the basolateral amygdala before a memory reactivation session disrupted the drug-associated memory and abolished subsequent instrumental responding for conditioned reinforcement. This effect was memory reactivation dependent, and the memory deficit persisted for at least 4 weeks. In contrast, infusion of D-APV immediately after the memory reactivation session had no effect on subsequent responding for conditioned reinforcement, indicating that NMDA receptors have a temporally limited role in the reconsolidation process. Furthermore, in molecular studies, we show that the reconsolidation-impairing effect of D-APV is correlated with downstream reductions in expression of the plasticity-related immediate early gene, zif268. We also demonstrate that systemic antagonism of NMDA receptors with MK-801 [(+)-5-methyl-10,11-dihydro-SH-dibenzo[a,d]cyclohepten-5,10-imine maleate] before memory reactivation subsequently reduced previously acquired instrumental drug-seeking behavior that depends on drug-associated cues acting as conditioned reinforcers. These data suggest that drugs modulating glutamatergic transmission at the NMDA receptor may be useful in the future treatment of relapse prevention in drug addiction through memory reconsolidation blockade.
...Der er nok er stykke vej før den behandlingsmodel kommer på tale til mennesker... Stoffet APV (en kompetitiv antagonist) bliver indgivet ved infusion direkte i amygdala. De nævner dog også kort at de ser en vis effekt ved systemisk behandling med MK-801.